Supplementary Figure S6 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

IHC staining of WM3965 PDX tumors treated with indicated compounds after 3 day of dosing and 4 hours post last dose for Ki67 (upper row) and cleaved caspase 3 (lower row).